Avalo Therapeutics AVTX
NASDAQ AVTX
$14.99 +0.04 (+0.27%)
At close: Oct 2, 2026 · 4:00 PM EDT

Avalo Therapeutics (AVTX) Depreciation & Amortization (CF) (2014 - 2026)

Updated

Avalo Therapeutics' Depreciation & Amortization (CF) came in at $17,000 for Q2 2026, down 87.3% from $134,000 a year earlier and unchanged from the prior quarter.

Analysis

Avalo Therapeutics (AVTX) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Avalo Therapeutics reported Depreciation & Amortization (CF) of $109,000, down 70.6% year-over-year; for FY2025, it was $344,000, up 103.6% from FY2024.

  • Depreciation & Amortization (CF) carries a five-year compound annual growth rate of -28.5% (FY2020 to FY2025).
  • Going back by year, Depreciation & Amortization (CF) was $169,000 in FY2024 (+7.0%), $158,000 in FY2023 (-4.8%), $166,000 in FY2022 (-90.0%) and $1.66 million in FY2021 (-10.1%).
  • The five-year range for quarterly Depreciation & Amortization (CF) is $16,000 (Q4 2025) to $455,000 (Q3 2021).
  • Year-over-year, Depreciation & Amortization (CF) has declined for three consecutive quarters, with growth averaging 58.3% over the last eight quarters.
  • The fastest year-over-year change in Depreciation & Amortization (CF) over five years came in Q2 2025 (growth of 306.1%), and the weakest in Q2 2022 (a decline of 93.4%).
  • Business Quant data shows AVTX's Depreciation & Amortization (CF) at $17,000 (Q1 2026), $16,000 (Q4 2025) and $59,000 (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 534.00 Mn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 1.96 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 194.00 Mn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 599.00 Mn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 1.93 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 1.11 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 98.00 Mn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 1.62 Bn
10 Avalo Therapeutics 653.59 Mn 653.59 Mn - 17,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 17,000.00
Mar 31, 2026 17,000.00
Dec 31, 2025 16,000.00
Sep 30, 2025 59,000.00
Jun 30, 2025 134,000.00
Mar 31, 2025 135,000.00
Dec 31, 2024 68,000.00
Sep 30, 2024 34,000.00
Jun 30, 2024 33,000.00
Mar 31, 2024 34,000.00
Dec 31, 2023 43,000.00
Sep 30, 2023 41,000.00
Jun 30, 2023 41,000.00
Mar 31, 2023 33,000.00
Dec 31, 2022 35,000.00
Sep 30, 2022 34,000.00
Jun 30, 2022 30,000.00
Mar 31, 2022 67,000.00
Dec 31, 2021 295,000.00
Sep 30, 2021 455,000.00
API Access

Avalo Therapeutics Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=AVTX&period=max&api_key=YOUR_API_KEY